Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Launched by DECIPHERA PHARMACEUTICALS, LLC · May 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called DCC-2812 for patients with advanced kidney cancer, bladder cancer, or prostate cancer that no longer responds to hormone therapy. The goal is to see if this medication is safe and if it can help fight these types of cancer. The study will take place at multiple locations and is currently not recruiting participants, meaning they haven't started enrolling patients yet.

To be eligible for this trial, participants must have a confirmed diagnosis of one of the cancers mentioned and be able to take medication by mouth. Women who can become pregnant need to have a negative pregnancy test before joining the study and must agree to use contraception during the trial. Participants should also have healthy organ function and certain levels of minerals in their blood. However, people who have had recent cancer treatments, significant heart problems, or major surgery in the last month will not be able to participate. If you qualify and decide to join, you can expect regular check-ups and monitoring to ensure your safety throughout the trial.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Have confirmed Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer
• • Able to take oral medication
• • If a female is of childbearing potential, must have a negative pregnancy test prior to enrollment and all participants agree to follow the contraception requirements
• • Adequate organ function and electrolytes
• Key Exclusion Criteria:
• • Received any prior anticancer therapy or any investigational therapy within a specified timeframe prior to first dose of DCC-2812
• • Impaired cardiac function
• • Major surgery within 28 days of the first dose of study drug